Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

570

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
TuberculosisAidsHiv Infections
Interventions
DRUG

Nevirapine based therapy

"* Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~* Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)"

DRUG

Efavirenz based therapy

Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)

DRUG

Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)

"* Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~* Continuation phase: 4 months daily H(RMP).~* Patients with meningitis will receive Streptomycin instead of E during intensive phase."

Trial Locations (3)

Unknown

Health centre of Alto Mae, Chamanculo district, Maputo

Health centre of Josue Macao, Maputo

Health centre of Malavane, Maputo

All Listed Sponsors
collaborator

Medecins Sans Frontieres, Netherlands

OTHER

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

NCT00495326 - Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) | Biotech Hunter | Biotech Hunter